tbuckley/cabot-search huggingface dataset:
Small increase in alcohol duty may cut violence related emergency department visits
Authors: Susan Mayor
Journal: BMJ (2016)

A small increase of just 1% above inflation in the duty imposed on alcohol sold in retail outlets, pubs, and restaurants could reduce violence related emergency department attendances by 6000 a year across England and Wales, a modelling study has estimated.1

This approach may be more effective at reducing injuries sustained through violence than minimum unit pricing for alcohol, the researchers said. Alcohol consumption has been linked to increased aggression and risk of injury, and a link also …
Multicenter Phase II Study of the CyclOBEAP Regimen for Patients with Peripheral T-Cell Lymphoma with Analysis of Biomakers.
Authors: Nozomi Niitsu, Miyuki Hayama, Yuki Hagiwara, Ken Tanae, Mika Kohri, Naoki Takahashi, Shigeo Nakamura, Jun-ichi Tamaru, Masataka Okamoto
Journal: Blood (2010)
AB0464 The Rate of and Risk Factors for Frequent Hospitalization in Systemic Lupus Erythematosus: Results from The Korean Lupus Network Registry
Authors: K.-E. Lee, J.-W. Lee, D.-J. Park, Y.-R. Yim, J.-E. Kim, L. Wen, S.-S. Lee
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> The survival rate of patients with systemic lupus erythematosus (SLE) has improved in the last few decades, but the rate of hospitalization and health care costs for these patients remain higher than in the general population. Thus, we evaluated the rate of hospitalization and associated risk factors in an inception cohort of Korean patients with lupus. <h3>Methods</h3> Of the 507 patients with SLE enrolled in the KORean lupus NETwork (KORNET registry), we investigated an inception cohort consisting of 196 patients with SLE presenting within 6 months of diagnosis based on the ACR classification criteria. We evaluated the causes of hospitalization, demographic characteristics, and laboratory and clinical data at the time of SLE diagnosis of hospitalized patients and during a follow-up period. We calculated the hospitalization rate as the number of total hospitalizations divided by the disease duration, and defined “frequent hospitalization” as hospitalization more than once per year. <h3>Results</h3> Of the 196 patients, 117 (59.6%) were admitted to hospital a total of 257 times during the 8-year follow-up period. Moreover, 22 (11.2%) patients were hospitalized frequently. The most common reasons for hospitalization included disease flares, infection, and pregnancy-related morbidity. In the univariate regression analysis, malar rash, arthritis, pericarditis, renal involvement, fever, SLE disease activity index &gt;12, hemoglobin level &lt;10 mg/dl, albumin level &lt;3.5 mg/dl, and anti–Sjögren9s syndrome A (SS-A) positivity were associated with frequent hospitalization. Finally, multivariate analysis showed that arthritis, pericarditis, and anti–SS-A antibody positivity at the time of diagnosis were risk factors for frequent hospitalization. <h3>Conclusions</h3> Our results showed that frequent hospitalization occurred in 11.2% of hospitalized patients and arthritis, pericarditis, and anti–SS-A antibody positivity at the time of diagnosis were risk factors for frequent hospitalization. <h3>Disclosure of Interest</h3> None declared
THU0352 Worldwide Heterogeneous Diagnostic Approach To Primary Sjögren Syndrome in 8315 Patients (EULAR-SS Task Force Big Data Sjögren Project)
Authors: P. Brito-Zeron, N. Acar-Denizli, M. Zeher, A. Rasmussen, R. Seror, T. Mandl, X. Li, C. Baldini, J.-E. Gottenberg, D. Danda, L. Quartuccio, R. Priori, G. Hernández-Molina, A. Kruize, V. Valim, M. Kvarnstrom, D. Sene, E. Bartoloni, S. Praprotnik, D. Isenberg, R. Solans, M. Rischmueller, S.-K. Kwok, G. Nordmark, Y. Suzuki, R. Giacomelli, V. Devauchelle-Pensec, M. Bombardieri, B. Hofauer, H. Bootsma, D. Hammenfors, G. Fraile, S. Carsons, T. Gheita, J. Morel, C. Vollenveider, F. Atzeni, S. Retamozo, I.-F. Horvath, K. Sivils, E. Theander, P. Sandhya, S. De Vita, J. Sanchez-Guerrero, E. van der Heijden, V. Moça-Trevisano, M. Wahren-Herlenius, X. Mariette, M. Ramos-Casals
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To analyse the diagnostic approach used in the largest international cohort of patients with primary Sjögren syndrome (pSS) <h3>Methods</h3> The Big Data Sjögren Project is a multicentre registry formed in 2014 by experts participating in the EULAR-SS Task Force. By January 2016, the database included 8315 consecutive patients fulfilling the 2002 criteria. The main features at diagnosis/recruitment (time of criteria fulfilment) were collected and analysed <h3>Results</h3> The cohort included 7753 (93%) women (mean age at diagnosis 53 years). Sicca symptoms were reported in more than 90% of patients at diagnosis (92% for dry eye and 92.5% for dry mouth). The diagnostic tests used included the determination of anti-Ro/La antibodies in 8250 (99%) patients, Schirmer test in 6205 (75%), salivary gland biopsy in 5988 (72%), salivary flows in 4941 (59%), corneal stainings in 3304 (40%), scintigraphy in 2578 (31%) and sialography in 873 (10%) patients. The mean number of diagnostic tests included in the 2002 AE criteria was 4.85 ± 1.44 (of a maximum of 8 different tests), and was higher in patients with negative ANA (5.18 vs 4.80 in ANA+, p&lt;0.001) or negative RF (5.06 vs 4.81 in RF+, p&lt;0.001), and was also higher in American patients vs European or Asian patients (5.28 vs 4.83 and 4.63, respectively). A correlation was found between the number of tests carried out and the number of 2002 criteria finally fulfilled (R=0.48) <h3>Conclusions</h3> We found a heterogeneous diagnostic approach of pSS with respect to the number of 2002AE diagnostic tests carried out; the approach varied significantly according to geographic origin and baseline immunological profile <h3>Disclosure of Interest</h3> None declared
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
Authors: Bruce Strober, Craig Leonardi, Kim A. Papp, Ulrich Mrowietz, Mamitaro Ohtsuki, Robert Bissonnette, Laura K. Ferris, Carle Paul, Mark Lebwohl, Daniel K. Braun, Lotus Mallbris, Stefan Wilhelm, Wen Xu, Anders Ljungberg, Nayan Acharya, Kristian Reich
Journal: Journal of the American Academy of Dermatology (2016)

Safety of biologics is important when treating patients with psoriasis.We sought to determine the safety of ixekizumab in psoriasis.Integrated safety data are presented from a 12-week induction period, a 12- to 60-week maintenance period, and from all ixekizumab-treated patients from 7 clinical trials. Exposure-adjusted incidence rates (IRs) per 100 patient-years are reported.Overall, 4209 patients received ixekizumab (total exposure: 6480 patient-years). During the induction period, the IRs of patients experiencing 1 or more treatment-emergent adverse event (AE) were 251 and 236 among ixekizumab- and etanercept-treated patients, respectively, and for serious AEs was 8.3 in both groups. During maintenance, for ixekizumab, the IRs of treatment-emergent AEs and serious AEs were 100.4 and 7.8, respectively. Among all ixekizumab-treated patients from 7 trials, the IR of Candida infections was 2.5. The IRs of treatment-emergent AEs of special interest (including serious infections, malignancies, major adverse cardiovascular events) were comparable for ixekizumab and etanercept during the induction period.Additional long-term data are required.Ixekizumab had an acceptable safety profile with no unexpected safety findings during ixekizumab maintenance in psoriasis.
The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific
Authors: G La Ruche, A Tarantola, P Barboza, L Vaillant, J Gueguen, M Gastellu-Etchegorry, None for the epidemic intelligence team at InVS
Journal: Eurosurveillance (2009)

There are few structured data available to assess the risks associated with pandemic influenza A(H1N1)v infection according to ethnic groups. In countries of the Americas and the Pacific where these data are available, the attack rates are higher in indigenous populations, who also appear to be at approximately three to six-fold higher risk of developing severe disease and of dying. These observations may be associated with documented risk factors for severe disease and death associated with pandemic H1N1 influenza infection (especially the generally higher prevalence of diabetes, obesity, asthma, chronic obstructive pulmonary disease and pregnancy in indigenous populations). More speculative factors include those associated with the risk of infection (e.g. family size, crowding and poverty), differences in access to health services and, perhaps, genetic factors. Whatever the causes, this increased vulnerability of indigenous populations justify specific immediate actions in the control of the current pandemic including primary prevention (intensified hygiene promotion, chemoprophylaxis and vaccination) and secondary prevention (improved access to services and early treatment following symptoms onset) of severe pandemic H1N1 influenza infection.
PARE0007 A Succesfull Caps Recycling Progect “Not Satiate Caps”
Authors: A. Phoka Charalambous
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The organization in the effort to implement the goal of social integration of people with RMDs and improve their self-service in order to feel independent and to have self-esteem, presented a need for providing free self-help tools to the members of the association. The need was created because of the economic crisis that exists in the country with all its consequences and, therefore, the high cost of living and reduced resources of people with Rheumatism. <h3>Objectives</h3> The main objective is to gain funds for the provision of self-help tools for everyday life and assessment and configuration of house and workplace, of people with Rheumatism. At the same time, the organization aims in The Raise Awareness of Rheumatism and The Raise of Volunteerism. <h3>Methods</h3> Use of recycling of caps in order to gain funds. As a result of the public interest, the organization decided to expand the campaign in the Junior and Kindergarten Schools because, children of this age are the best means to transfer the messages we want to convey to society. A collaboration with a Big Insurance Company started for this project, who sponsored the amount of 90000€. The Ministry of Education and Culture became an important supporter and the Media were involved too. Eventually, the recycling company agreed to enlarge their collecting program. Through this program, we invite children to collect plastic caps from water containers, milk, and any other plastic caps, and place them in yellow plastic bins bought specifically for this purpose by the sponsor and placed in schools. <h3>Results</h3> More than 210 schools have declared their participation from the 2 bigger cities in the country. Leaflets have been prepared to share to all students in the schools for informing them and their families about the project, RMD9s and organization. A presentation has been also prepared to be shown to students by volunteers in the schools. TV and radio advertisements have been prepared with the slogan "Not satiate caps". A special website has been developed which a simple and understandable educational tool for children on recycling issues and rheumatic diseases as well as for the actions of the program. A Press Conference has been made for the Campaign by the Organization together with the Ministry of Education and Culture, and the big Sponsor. A competition was launched between the schools participating in the program, with the first three schools from each district being awarded at a special ceremony to be held in May 2016, the total amount of 10,000€. <h3>Conclusions</h3> This campaign has successfully managed to: fund raise a big amount for help-self tools to be able to give them free to organization9s members to Raise Awareness primarily for the RMD9s and the Organization, and last but not least the Protection of the Environment and recycling and to Raise Volunteerism by building the next generation of volunteers. <h3>Disclosure of Interest</h3> None declared
Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis
Authors: Ayalew Tefferi, Aref Al-Kali, Kebede H. Begna, Mrinal M Patnaik, Terra L. Lasho, Xiaolin Wang, Ying Wan, Curtis A. Hanson
Journal: Blood (2015)
Germinal Center Specific Activation of K-Ras, Common In Multiple Myeloma, Is Selected Against and Is Not Sufficient to Initiate Plasma Cell Transformation In Mice
Authors: Chelsea D. Mullins, Michael Tomasson, Lan Lu, Mack Y. Su, Vishwanathan Hutchagowder, Ravi Vij, Shashikant Kulkarni, Liang Chu
Journal: Blood (2010)
A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas
Authors: Jennifer L. Cultrera, Jijun Liu, Idalia Liboy, Celeste M. Bello, Lubomir Sokol, Eduardo M. Sotomayor, Enrique Santana, Fernando Cabanillas
Journal: Blood (2010)
Age-Associated DNA Methylation Signature Reveals Premature Aging In Patients With Aplastic Anemia and Dyskeratosis Congenita Which Correlates With Telomere Shortening
Authors: Fabian Beier, Carola I. Weidner, Qiong Lin, Patrick Ziegler, Martin Zenke, Tim H. Brümmendorf, Wolfgang Wagner
Journal: Blood (2013)
PWE-013 Should The Target TGN Range Be Different in Those with Intermediate Compared with Normal TPMT Activity?
Authors: EL Johnston, BD Warner, SC Fong, MG Ward, V Kariyawasam, M Arenas-Hernandez, TM Marinaki, JD Sanderson, PA Blaker
Journal: Gut (2016)

<h3>Introduction</h3> Thioguanine nucleotides (TGNs) are the biologically active metabolites of thiopurines. Methylated thiopurine metabolites (MeMPs) formed via thiopurine-<i>S</i>-methyltransferase (TPMT) may also have immunosuppressive properties through inhibition of de novo purine synthesis (<i>DNPS</i>).<sup>1</sup> Individuals with intermediate TPMT activity do not produce significant levels of methylated metabolites, with predictably less inhibition of <i>DNPS </i>and therefore may tolerate higher levels of TGNs. If confirmed this suggests that the therapeutic range of TGNs (240–450 pmol/8x10<sup>8</sup>) may differ between patients with intermediate Vs normal TPMT activity. <h3>Methods</h3> All IBD patients at Guy’s and St Thomas’ Hospitals treated with either azathioprine or mercaptopurine who had TGNs measured from 2002–2013 were included. Patients receiving low dose thiopurine with allopurinol were excluded. Data was collected using the electronic patient record system and statistical analysis was completed in GraphPad Prism version 5.0. <h3>Results</h3> 2193 TGN measurements were included in the analysis, 340 (15.5%) from patients with intermediate TPMT activity and the remaining 1853 had normal TPMT activity. The average normalised thiopurine doses between groups was 1.13 Vs 1.87 mg/kg/day respectively, reflecting standard dose adjustment in intermediate TPMT patients. The median TGNs levels were significantly higher in patients with intermediate Vs normal TPMT activity; 370 Vs 277 pmol/8x10<sup>8</sup> (P = &lt;0.00001) and the median MeMP levels were lower in patients with intermediate Vs normal TPMT activity; 104 pmol/8x10<sup>8</sup> RBC Vs 566 (P = &lt;0.0001). No significant difference was found in the median values of Hb, WBCs, neutrophil or platelet counts between the groups. A lower lymphocyte count (1.3 Vs 1.2 x109/<sup>9</sup>/ L, P = 0.0010) and trend towards a higher MCV (93 Vs 94, P = 0.0625) was noted in patients with normal TPMT activity. <h3>Conclusion</h3> Despite significantly higher TGN levels in patients with intermediate as compared to normal TPMT activity, there was no difference in levels of Hb, WBCs, neutrophil or platelets counts. This suggests a greater tolerance to TGNs in patients with intermediate TPMT activity and may indicate that a different TGN therapeutic range is needed in these patients. The likely reason is that methylated metabolites are biologically active and also play a role in overall thiopurine immunosuppression. <h3>Reference</h3> 1 Tay BS, Lilley RM, Murray AW, <i>et al</i>. Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. <i>Biochemical Pharmacology</i>. 1969;<b>18</b>(4):936–8. <h3>Disclosure of Interest</h3> None Declared
Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis
Authors: Kumudha Balakrishnan, Marisa Peluso, Min Fu, Nathalie Y. Rosin, Jan A. Burger, William G. Wierda, Michael J. Keating, Kerrie Faia, Susan O'Brien, Jeff Kutok, Karen McGovern, Varsha Gandhi
Journal: Blood (2013)
SAT0135 Achieving Freedom from Glucocorticoids Might Decrease Risk of Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of The Tomorrow Study: Table 1.
Authors: S. Anno, K. Inui, K. Mamoto, T. Okano, Y. Sugioka, M. Tada, T. Koike, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falls and fractures. <h3>Objectives</h3> The present study prospectively investigates correlations between decreasing doses of glucocorticoid (GC) and the incidence of clinical fractures in patients with RA based on the five-year findings of the TOMORROW study (UMIN000003876) that started in 2010. <h3>Methods</h3> We evaluated anthropometric parameters, bone mineral density, disease activity, RA medication, and the incidence of clinical fractures over a period of five years in 202 patients with RA (mean age, 58.6 years; mean disease duration, 14.0 years). We also assessed the effects of GC doses on the incidence of clinical fractures over the same period in patients with RA using multivariate regression analysis. <h3>Results</h3> The incidence of clinical fractures in patients with RA was 0.042/person-years (py). There were 87 RA patients (41.8%) treated with GC whose incidence rate and number of clinical fractures were significantly higher than those without GC treatment (27.4% vs. 11.9%; p=0.008; 0.063 vs. 0.012 py; p=0.012, respectively). After adjusting for fracture risk factors including age, sex, smoking, and body mass index, multivariate logistic regression analysis revealed that GC administered within the five-year period was a significant risk factor for clinical fractures (odds ratio [OR], 2.58; 95% confidence interval [CI], 1.22–5.44, p=0.013). A mean GC dose during the 5-year period of ≥2 mg/day increased risk for fractures in patients with RA (OR 3.48; Table 1). Although only reducing the GC dose did not decrease the risk of clinical fractures in patients with RA, risk was significantly lowered when the dose was reduced to zero within the five-year period (OR 0.21; Table 1). <h3>Conclusions</h3> Medication with GC was a significant risk factor for clinical fractures, and low doses are apparently significantly associated with an increased frequency of fractures among patients with RA. However, reducing the GC dose to zero among RA patients within five-years could lower the risk for clinical fractures. We concluded that GC medication should be tapered to zero over a period of five years in patients after RA activity is controlled. <h3>Disclosure of Interest</h3> None declared
AB0947 The Role of Musculoskeletal Ultrasound in Managing Systemic Lupus Erythematosous and Sjogren's Syndrome in A Real Life Clinic: Table 1.
Authors: E. Ntatsaki, B. Gracia-Tello, C. Ciurtin
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Musculoskeletal Ultrasound Assessment (US) is increasingly used as a valid and reliable tool for guiding the management of inflammatory arthritides. However its use in Systemic Lupus Erythematosous (SLE) and Sjogren9s Syndrome (SS) in clinical practice remains limited<sup>1</sup>, thus potentially missing an opportunity to appreciate severity of joint involvement and optimise management<sup>2</sup>. <h3>Objectives</h3> To analyse a real life cohort of SLE and SS patients referred for US assessment on clinical grounds, to review their characteristics and whether US assessment led to a change in treatment. <h3>Methods</h3> Retrospective analysis of real life data from a dedicated rheumatology US clinic at a tertiary referral hospital. The OMERACT scoring system was used for the US examination of 22 hand joints in every patient (wrists, metacarpo-phalangeal and proximal interphalangeal (PIP) joints bilaterally). <h3>Results</h3> Over a 2 year period (01/2014–12/2015) a total of 604 patients were scanned including 19 with SLE and 17 with SS. Patient characteristics and differences between their US outcomes are shown in table 1. US assessment prompted treatment change in 84% of SLE patients and 82% of SS cohort. ESR showed a better association with swollen joint count in SS (r=0.29) than SLE (r=0.17), however this did not reach statistical significance. A subanalysis of the SLE cohort showed poor correlation of the MSK BILAG items scores with active joint disease defined as PD presence on US (r=0.189, p=0.5). <h3>Conclusions</h3> US assessment led to significant change in management for both cohorts. The SLE group had more active disease on US than SS, despite similar swollen joint count and increased prednisolone. There was poor correlation of US disease activity and MSK BILAG in SLE patients, suggesting that US can provide additional information in identifying active joint disease. US proves a useful and reliable tool to monitor musculoskeletal features and therapeutic outcomes in both SLE and SS patients that can be used routinely in real life clinical practice. <h3>References</h3> Zayat AS et al. The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. Rheumatology (Oxford). 2015 Oct 7 Mosca, M et al. The role of imaging in the evaluation of joint involvement in 102 consecutive patients with systemic lupus erythematosus. Autoimmun Rev. 2015 Jan;14(1):10–5 <h3>Disclosure of Interest</h3> None declared
Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).
Authors: Angela Poerio, Marilina Amabile, Ilaria Iacobucci, Simona Soverini, Sabrina Colarossi, Emanuela Ottaviani, Carolina Terragna, Tiziana Grafone, Simona Luatti, Fausto Castagnetti, Fabrizio Pane, Giuseppe Saglio, Domenico Russo, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2005)
Ten Years of Cerebral Venous Thrombosis (CVT) in Melbourne, Australia: Male Gender and Presence of Myeloproliferative Neoplasm Is Associated with Thrombotic Recurrence in Unprovoked Events
Authors: Hui Yin Lim, Cheryl Ng, Carole L. Smith, Geoffrey Donnan, Harshal Nandurkar, Prahlad Ho
Journal: Blood (2015)